Open Access<p>Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice</p>
Author(s) -
Ye Zhu,
Zeliang Li,
Ao Ding,
Hui Yang,
Wei Zhu,
Tongxia Cui,
Huitao Zhang,
Hua Zhang
Publication year - 2019
Publication title -
drug design, development and therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s217826
Subject(s) - olmesartan , medicine , pharmacology , angiotensin receptor , angiotensin ii , receptor , endocrinology , blood pressure
Diabetic nephropathy (DN) is a common complication of diabetes mellitus (DM) and also a major cause of end-stage renal disease (ESRD). Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and has been shown to exhibit renoprotective effects on a streptozotocin (STZ)-induced diabetic rat model. Yet, whether OM affects DN progression and renal injury in db/db mice, a type 2 diabetic murine model, has not been established.